Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2850962
Reference Type
Journal Article
Title
Reductions in serum lipids with a 4-year decline in serum perfluorooctanoic acid and perfluorooctanesulfonic acid
Author(s)
Fitz-Simon, N; Fletcher, T; Luster, MI; Steenland, K; Calafat, AM; Kato, K; Armstrong, B
Year
2013
Is Peer Reviewed?
Yes
Journal
Epidemiology
ISSN:
1044-3983
EISSN:
1531-5487
Volume
24
Issue
4
Page Numbers
569-576
Language
English
PMID
23685825
DOI
10.1097/EDE.0b013e31829443ee
Web of Science Id
WOS:000320305900013
Relationship(s)
has erratum
5079945
Reductions in serum lipids with a 4-year decline in serum perflourooctanoic acid and perfluorooctanesulfonic acid (vol 24, pg 569, 2013)
Abstract
BACKGROUND:
Several epidemiological cross-sectional studies have found positive associations between serum concentrations of lipids and perfluorooctanoic acid (PFOA, or C8). A longitudinal study should be less susceptible to biases from uncontrolled confounding or reverse causality.
METHODS:
We investigated the association between within-individual changes in serum PFOA and perfluorooctanesulfonic acid (PFOS) and changes in serum lipid levels (low-density lipoprotein [LDL] cholesterol, high-density lipoprotein cholesterol, total cholesterol, and triglycerides) over a 4.4-year period. The study population consisted of 560 adults living in parts of Ohio and West Virginia where public drinking water had been contaminated with PFOA. They had participated in a cross-sectional study in 2005-2006, and were followed up in 2010, by which time exposure to PFOA had been substantially reduced.
RESULTS:
Overall serum concentrations of PFOA and PFOS fell by half from initial geometric means of 74.8 and 18.5 ng/mL, respectively, with little corresponding change in LDL cholesterol (mean increase 1.8%, standard deviation 26.6%). However, there was a tendency for people with greater declines in serum PFOA or PFOS to have greater LDL decrease. For a person whose serum PFOA fell by half, the predicted fall in LDL cholesterol was 3.6% (95% confidence interval = 1.5-5.7%). The association with a decline in PFOS was even stronger, with a 5% decrease in LDL (2.5-7.4%).
CONCLUSIONS:
Our findings from this longitudinal study support previous evidence from cross-sectional studies of positive associations between PFOA and PFOS in serum and LDL cholesterol.
Tags
PFAS
•
Additional PFAS (formerly XAgency)
Literature Search November 2019
Other Sources
ATSDR
Screened Studies
Excluded
Exclude (TIAB)
•
Expanded PFAS SEM (formerly PFAS 430)
Litsearch: September 2019
PubMed
Not prioritized for screening
Perfluorooctane
Potassium perfluorooctanoate
Sodium perfluorooctanoate
•
PFAS 150
Literature Search Update December 2020
PubMed
Literature Search August 2019
PubMed
Web of Science
Not prioritized for screening
Ammonium perfluorooctanoate
Perfluorooctane
Perfluorooctanesulfonic acid
Perfluorooctanoic acid
•
PFAS Universe
Data Source
Web of Science
Pubmed
Perfluorooctanesulfonate
Perfluorooctanesulfonic acid
Perfluorooctanoate
Perfluorooctanoic acid
•
PFHxS
OW - HHRAB
•
PFOA (335-67-1) and PFOS (1763-23-1)
Literature Search Update (2013-2019)
PubMed
WOS
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity